Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Université Bordeaux Segalen, University of Bologna, Memorial Sloan Kettering Cancer Center, South Australia Pathology, South Australian Health and Medical Research Institute, Centre for Cancer Biology, The University of Adelaide, Ospedale San Luigi Gonzaga, University of Turin, Tennessee Oncology, Novartis (Switzerland), Novartis (Austria), Jena University Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2597789345